How Much Does Farxiga (Dapagliflozin) Cost in Massachusetts in 2026?

Retail and Cash-Pay Pricing Across Massachusetts

The average cash price for brand-name Farxiga at Massachusetts retail pharmacies sits at approximately $620 per month for a 30-day supply of 10 mg tablets [1]. That figure reflects AstraZeneca's wholesale acquisition cost and has remained relatively stable through the first half of 2026. Prices vary by pharmacy. Independent pharmacies sometimes charge $10 to $30 less than large chains, though the difference is modest relative to the total cost.

Without insurance or a savings card, $620 per month puts Farxiga well above what most patients can absorb out of pocket. For context, this places dapagliflozin in the same pricing tier as empagliflozin (Jardiance), which also lists near $600 per month. No FDA-approved generic dapagliflozin exists in the U.S. market as of May 2026, so there is no automatic lower-cost substitution at the pharmacy counter [1].

Patients filling prescriptions at Costco, Amazon Pharmacy, or Mark Cuban's Cost Plus Drugs should compare prices directly, as each platform negotiates different rates. GoodRx and RxSaver coupons may bring the cash price into the $480 to $560 range at select Massachusetts locations, but these discounts fluctuate month to month. The most reliable cost reduction for commercially insured patients remains the manufacturer savings card, discussed below.

Massachusetts Medicaid (MassHealth) Coverage

MassHealth covers Farxiga, but requires prior authorization [2]. The prescribing clinician must document that the patient meets specific clinical criteria, typically a diagnosis of type 2 diabetes with inadequate glycemic control on metformin, established heart failure with reduced ejection fraction (HFrEF), or chronic kidney disease (CKD) at risk of progression.

The prior authorization process in Massachusetts generally takes 24 to 72 hours. Denials are most often due to incomplete documentation rather than a clinical coverage exclusion. If a prescriber submits chart notes showing an eGFR between 25 and 75 mL/min/1.73 m² alongside a diagnosis of CKD, approval rates are high, given the strength of the DAPA-CKD trial data showing a 39% reduction in the composite kidney endpoint [3].

For MassHealth managed care enrollees (plans like BMC HealthNet, Fallon, or Tufts Health Together), formulary placement may differ slightly from fee-for-service MassHealth. Patients should verify their specific plan's preferred drug list. Step therapy requirements sometimes mandate a trial of metformin or an ACE inhibitor/ARB before Farxiga approval, depending on the indication.

One practical note: if prior authorization is denied, MassHealth allows a formal appeal within 30 days. The appeal should include supporting clinical evidence. Citing the DAPA-HF trial, which demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death (HR 0.74 to 95% CI 0.65 to 0.85), strengthens heart failure appeals considerably [4].

Insurance Coverage: Commercial and Medicare Plans

Most major commercial insurers operating in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan, and Aetna, include Farxiga on their formularies. Placement is typically Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with monthly copays ranging from $25 to $75 depending on plan design [1].

Patients on high-deductible health plans face the full $620 until their deductible is met. This is where the AstraZeneca savings card becomes especially valuable (see next section).

Medicare Part D plans present a different situation. The Inflation Reduction Act capped annual out-of-pocket prescription drug costs at $2,000 for Medicare Part D enrollees starting in 2025 [5]. For patients taking Farxiga year-round, the $2,000 cap is typically reached by March or April, after which cost-sharing drops to $0 for the remainder of the calendar year. Medicare patients cannot use manufacturer copay cards, but the annual cap provides meaningful protection against cumulative costs.

Medicare Advantage plans in Massachusetts (offered by carriers like UnitedHealthcare, Humana, and Aetna) may apply step therapy or require prior authorization before covering Farxiga. Formulary status varies by plan year, so patients should check their Evidence of Coverage document each January.

The AstraZeneca Savings Card: How It Works in Massachusetts

AstraZeneca offers a copay savings card for commercially insured patients that can reduce the out-of-pocket cost of Farxiga to as low as $0 per month [1]. The card covers up to a set dollar amount per prescription fill, and the specific cap depends on the current program terms (historically $150 to $175 per fill).

Eligibility requirements are straightforward. The patient must have commercial insurance (not Medicare, Medicaid, or any other government-funded plan). Massachusetts residents qualify under the same terms as patients in all other states. Enrollment is available through AstraZeneca's website or at the pharmacy counter with a printed or digital card.

The savings card works by covering the difference between the patient's copay or coinsurance and $0 (or a low residual amount). For example, if a patient's insurance sets a $50 copay for Farxiga, the savings card pays the full $50. If the plan requires $200 in coinsurance, the card covers up to its per-fill maximum, leaving the patient responsible for any overage.

There are limits. The card typically expires after 12 months and must be renewed. Patients on government insurance are ineligible. Some employer-sponsored plans with copay accumulator programs do not allow savings card payments to count toward the annual deductible, which can create unexpected cost spikes later in the year. Ask your pharmacist whether your plan uses a copay accumulator before relying on the card as a long-term strategy.

Compounded Dapagliflozin: Legality and Access in Massachusetts

Compounded dapagliflozin is available in Massachusetts through licensed 503A compounding pharmacies [6]. Under federal law, 503A pharmacies may compound medications based on a valid patient-specific prescription when a prescriber determines that the commercially available product is not appropriate for a given patient (for example, due to an allergy to an inactive ingredient in brand Farxiga, or a need for an alternative dosage form).

Massachusetts follows the standard 503A framework. The state Board of Registration in Pharmacy oversees compounding pharmacies operating within its borders and requires compliance with USP <795> standards for non-sterile compounding. Dapagliflozin, being an oral tablet, falls under non-sterile compounding guidelines.

Cost is a significant draw. Some 503A compounding pharmacies price compounded dapagliflozin well below the $620 brand cost, with some patients reporting out-of-pocket costs under $100 per month. Pricing varies by pharmacy, compounding volume, and whether the patient pays cash or uses insurance (most insurance plans do not cover compounded medications).

A few caveats apply. Compounded drugs are not FDA-approved, meaning they have not undergone the same bioequivalence testing as brand Farxiga [6]. The active ingredient is the same molecule, but the final product's dissolution rate, stability, and potency depend on the compounding pharmacy's quality controls. Patients considering this route should confirm that their pharmacy holds current accreditation (PCAB accreditation is voluntary but signals higher quality standards) and that their prescriber supports the switch.

"Compounded medications fill a real clinical need, but patients should understand that the regulatory oversight differs from FDA-approved products," notes the FDA's guidance on compounding. Discussing compounded alternatives with a prescriber who understands both the cost pressures and the quality considerations is the right starting point.

Farxiga via Telehealth in Massachusetts

Massachusetts permits telehealth prescribing of Farxiga. The state adopted permanent telehealth parity legislation in 2021, requiring insurers to cover telehealth visits at the same rate as in-person appointments [7]. This means a clinician licensed in Massachusetts can evaluate a patient via video or audio visit, prescribe dapagliflozin, and send the prescription electronically to a Massachusetts pharmacy.

Telehealth is particularly useful for follow-up visits and refill management. The initial diagnosis of type 2 diabetes, heart failure, or CKD typically requires lab work (HbA1c, eGFR, BNP), which still needs an in-person blood draw. But once the diagnosis is established and the patient is stable on Farxiga, ongoing management translates well to virtual care.

HealthRX and other telehealth platforms operating in Massachusetts can prescribe Farxiga if the provider holds an active Massachusetts medical license. Patients should verify that their insurance covers the specific telehealth platform they choose, as some plans restrict coverage to in-network providers or specific telehealth vendors.

Clinical Value: Why Farxiga Is Worth the Investment

The cost of Farxiga is easier to justify when measured against its clinical evidence base. Three large randomized controlled trials established dapagliflozin's benefit across its approved indications.

DAPA-HF (N=4,744) showed that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74 to 95% CI 0.65 to 0.85, P<0.001) in patients with HFrEF, regardless of diabetes status [4]. The number needed to treat (NNT) was 21 over a median 18.2-month follow-up.

DAPA-CKD (N=4,304) demonstrated a 39% reduction in the composite of sustained eGFR decline of at least 50%, end-stage kidney disease, or renal/cardiovascular death (HR 0.61 to 95% CI 0.51 to 0.72, P<0.001) [3]. The trial was stopped early for overwhelming efficacy. That early stop is rare in nephrology and signals a large treatment effect.

DECLARE-TIMI 58 (N=17,160), the cardiovascular outcomes trial for type 2 diabetes, showed that dapagliflozin reduced the composite of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83 to 95% CI 0.73 to 0.95) [8]. The hospitalization-for-heart-failure component drove most of the benefit.

Taken together, these trials support dapagliflozin's position as a guideline-recommended therapy. The 2022 AHA/ACC/HFSA heart failure guidelines give SGLT2 inhibitors a Class I recommendation for HFrEF and a Class IIa recommendation for HFpEF [9]. The KDIGO 2024 CKD guidelines recommend SGLT2 inhibitors for all patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², or those with eGFR 45 to 90 mL/min/1.73 m² and albuminuria (ACR ≥200 mg/g) [10].

"SGLT2 inhibitors have become a cornerstone of cardiorenal protection. The data from DAPA-HF and DAPA-CKD changed practice for millions of patients worldwide," stated the KDIGO executive summary [10].

Practical Steps to Minimize Your Farxiga Cost in Massachusetts

The cheapest path depends on your insurance status. Here is a decision sequence:

Commercially insured: Apply for the AstraZeneca savings card first. If your plan has a copay accumulator, ask your HR department whether switching to a plan without one is possible during open enrollment. Use GoodRx or RxSaver as a backup if the savings card is unavailable.

MassHealth (Medicaid): Work with your prescriber to submit prior authorization documentation early. Include the specific FDA-approved indication and supporting lab values. If denied, appeal with trial citations.

Medicare Part D: Confirm your plan's formulary tier. Budget for higher out-of-pocket costs in January through March before hitting the $2,000 annual cap. If your plan does not cover Farxiga, file a coverage determination request or switch plans during open enrollment.

Uninsured or underinsured: Explore AstraZeneca's patient assistance program (AZ&Me), which provides Farxiga at no cost to qualifying patients with household incomes at or below 400% of the federal poverty level [1]. Ask your prescriber about compounded dapagliflozin from a licensed 503A pharmacy as a lower-cost alternative.

For all patients: fill 90-day supplies when possible to reduce per-unit cost and pharmacy dispensing fees, and confirm with your provider that the 10 mg dose is appropriate (Farxiga is available in 5 mg and 10 mg strengths, and some patients start at 5 mg before titrating up).